Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD07805/47 gel for persistent facial erythema
NCT01882712Phase 3Withdrawn
- Sponsor
- Galderma
- Primary completion
- Sep 2015
01
Overview
Phase 3, randomised, double-blind trial of placebo-Galderma R&D-erythematotelangiectatic rosacea in erythema (2 arms), sponsored by Galderma. Primary endpoint: Composite success on both Clinician Erythema Assessment (CEA) and Patient Self Assessment (PSA) at 29 days. Status: withdrawn.
02
Drugs
placebo-Galderma R&D-erythematotelangiectatic rosacea
03
Conditions
erythema
Beyond the preview
Go deeper on NCT01882712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01882712.